<DOC>
	<DOCNO>NCT01318070</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety alogliptin , daily ( QD ) combine thiazolidine take QD type 2 diabetic patient uncontrolled blood glucose .</brief_summary>
	<brief_title>Efficacy Safety Alogliptin Used Combination With Thiazolidine Participants With Type 2 Diabetes Japan</brief_title>
	<detailed_description>Both insulin hyposecretion insulin-resistance consider involved development type 2 diabetes mellitus . Takeda develop SYR-322 ( alogliptin ) improvement glycemic control patient type 2 diabetes mellitus . Alogliptin inhibitor dipeptidyl peptidase IV ( DPP-IV ) enzyme . DPP-IV think primarily responsible degradation 2 peptide hormone release response nutrient ingestion . It expect inhibition DPP-IV improve glycemic control patient type 2 diabetes . The present study plan evaluate efficacy safety alogliptin add-on pioglitazone type 2 diabetic patient uncontrolled blood glucose despite treatment pioglitazone well diet exercise therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>1 . Had take pioglitazone stable dose ( 15 mg/day 30 mg/day ) least 16 week prior start treatment period ( Week 0 ) . 2 . Had glycosylated hemoglobin ( HbA1c ) 6.5 % 10.0 % 14 week start observation period ( Week 2 ) . 3 . Had HbA1c difference within 10.0 % * 10 week start observation period ( Week 6 ) 14 week start observation period ( Week 2 ) 10 week start observation period ( Week 6 ) ( *rounded first decimal place ) . 4 . Was receive specific diet exercise ( ) therapies observation period . 1 . Had take diabetic medication pioglitazone within 16 week start treatment period ( Week 0 ) . 2 . Had history symptom cardiac failure .</criteria>
	<gender>All</gender>
	<minimum_age>33 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Diabetes Mellitus - Type2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>